When the immune system attacks the nervous system by mistake, the results can be unpredictable and far-reaching. Seizures that begin without warning in an adult who has never had epilepsy. A rapid decline in memory and behaviour in someone who was cognitively well only weeks before. Muscle weakness that spreads without an obvious cause. Movement difficulties that resemble Parkinson’s disease but do not respond to standard treatment.
These are not rare curiosities. Autoimmune neurological disorders – conditions in which the body’s own immune response targets brain tissue, spinal cord, peripheral nerves, or the junction between nerves and muscles – represent one of the most rapidly expanding areas of modern neurology. Many of these conditions can be stabilised or significantly improved with appropriate treatment, but only if the correct diagnosis is made in time.
That is where specialist laboratory capability becomes critical. Amrita Hospital, Kochi, hosts what is described as the first dedicated neuroimmunology laboratory of its kind in India – a comprehensive testing facility for autoimmune neurological disorders, operating within the Department of Neurology under the direction of a trained clinical autoimmune neurologist.
What Are Autoimmune Neurological Disorders?
The immune system’s role is to identify and destroy foreign material – viruses, bacteria, and abnormal cells. In autoimmune neurological conditions, this system malfunctions and produces antibodies or inflammatory responses directed against the body’s own nervous system tissue.
The nervous system structures that can be affected include:
- The brain, including the limbic system (involved in memory, behaviour, and emotion)
- The spinal cord
- The peripheral nerves (those outside the brain and spinal cord)
- The neuromuscular junction (the point at which nerves connect to muscles)
- The cerebellum (the brain region governing coordination and balance)
Because the nervous system controls so many bodily functions, the symptoms of autoimmune neurological disorders are extraordinarily varied. The same immune-mediated mechanism can produce seizures in one patient, psychosis in another, movement disorder in a third, and weakness or sensory loss in a fourth. This variability is one reason these conditions are frequently misattributed to other causes in the early stages.
Why Are These Conditions Difficult to Diagnose?
Several factors make autoimmune neurological disorders challenging to identify.
First, the symptoms can closely mimic other neurological and psychiatric conditions. A patient presenting with new-onset psychiatric symptoms, memory disturbance, or unexplained seizures may initially be assessed for primary psychiatric illness, epilepsy, stroke, or metabolic encephalopathy – and may receive treatment for those conditions for months before an autoimmune cause is considered.
Second, standard investigations – routine blood tests, conventional brain MRI, and cerebrospinal fluid analysis – may appear normal or show only non-specific changes, particularly in the early stages.
Third, the specific antibodies responsible for many of these conditions were only characterised in the past two decades. Testing for anti-NMDAR antibodies, anti-LGI1, anti-CASPR2, anti-GABA-B, and many others requires specialised laboratory capability that is not available in most general pathology facilities.
Fourth, many clinicians outside of specialist centres have limited exposure to these conditions, making awareness and early suspicion less consistent.
The cumulative result of these factors is delayed diagnosis – often measured in months, and sometimes years.
Common Autoimmune Neurological Conditions
The range of recognised autoimmune neurological disorders has expanded significantly with advances in antibody testing. Among the more commonly encountered are:
Anti-NMDA receptor encephalitis – associated with psychiatric features, seizures, movement abnormalities, and reduced consciousness; more common in younger patients including children and young women, sometimes linked to an ovarian tumour
Anti-LGI1 encephalitis – presents with a distinctive pattern of brief, repetitive arm and face movements, followed by memory impairment; more common in older men
Neuromyelitis optica spectrum disorder (NMOSD) – an inflammatory condition of the optic nerves and spinal cord, historically misclassified as multiple sclerosis; associated with AQP4 and MOG antibodies
Autoimmune epilepsy – seizures driven by an underlying autoimmune mechanism that may not respond to standard anti-seizure medications
Myasthenia gravis – impairs neuromuscular transmission, causing fluctuating weakness particularly affecting the eyelids, facial muscles, and swallowing
Chronic inflammatory demyelinating polyneuropathy (CIDP) – a slowly progressive weakness and sensory loss caused by immune-mediated damage to peripheral nerve myelin
This list represents only a portion of recognised conditions. Research has described newer autoimmune neurological syndromes including autoimmune atypical Parkinsonism and other movement disorders with immune-mediated mechanisms – areas in which Amrita’s neuroimmunology programme is actively involved.
The Role of Antibody Testing in Diagnosis
Antibody testing does not establish a diagnosis on its own. A positive antibody result is one component of a clinical assessment that includes the patient’s symptoms, neurological examination findings, brain imaging, cerebrospinal fluid analysis, and in some cases, investigations to look for an underlying tumour that may be driving the immune response.
Equally, a negative antibody result does not rule out an autoimmune cause. Some patients with clinically suspected autoimmune encephalitis have seronegative disease – no identifiable antibody – and may still respond to immunotherapy.
What specialised antibody testing does is dramatically improve the probability of identifying a treatable immune-mediated cause in a patient who might otherwise continue on an incorrect diagnostic pathway.
Amrita’s Neuroimmunology Laboratory of Excellence
The Neuroimmunology Laboratory at Amrita Hospital, Kochi, is described as the first of its kind in India – a dedicated comprehensive testing facility for autoimmune neurological disorders, operating under a trained clinical autoimmune neurologist.
The laboratory provides the specialist antibody testing panel required to evaluate the conditions described above, as well as the clinical expertise to interpret results within the full context of the patient’s presentation.
The Department of Neurology at Amrita also includes associated research activity in autoimmune neurological disorders, including the description of newer autoimmune syndromes and the discovery of novel disease markers. This research orientation means the laboratory’s capability is not static – it is updated in line with developments in the field.
The Neuroimmunology Laboratory operates as part of the wider Centre for Neurosciences at Amrita, which is one of the largest neuroscience centres in southern India. The centre’s breadth – spanning neurology, neurosurgery, the Advanced Centre for Epilepsy, and the Comprehensive Sleep Centre – means that patients with complex or overlapping neurological presentations can be assessed across multiple disciplines within the same institution.
Sri Lankan patients can explore the full range of neurology and neuroscience services available at Amrita Hospital through the Amrita Info Centre Sri Lanka website.
What Happens After Diagnosis?
When an autoimmune neurological condition is identified, treatment typically involves immunotherapy – medications that reduce or modulate the immune response responsible for the neurological damage.
First-line treatments commonly include corticosteroids, intravenous immunoglobulin, and plasma exchange (plasmapheresis), depending on the severity and clinical context. If first-line treatment produces an incomplete response, second-line agents such as rituximab or mycophenolate mofetil may be used to achieve more sustained immune suppression.
In some cases – particularly where the autoimmune condition is associated with an underlying tumour – treatment of the tumour itself is a central part of the management plan.
Recovery varies considerably. Some patients recover substantially or completely, particularly when diagnosis and treatment occur early. Others experience a more protracted course. Not all autoimmune neurological disorders are fully reversible, and the extent of recovery depends on the specific condition, the duration of illness before treatment, and individual patient factors.
Ongoing follow-up is important because some of these conditions can relapse, requiring long-term monitoring and, in some cases, maintenance immunotherapy.
We have covered some aspects of epilepsy and its surgical treatment – including conditions that may have an autoimmune component – in our guide on epilepsy surgery in India for Sri Lankan patients.
Why Sri Lankan Patients Seek Specialist Evaluation in India
For Sri Lankan patients whose neurological symptoms have not been fully explained by investigations locally, referral to a specialist centre with dedicated neuroimmunology capability can be clinically significant.
The specific antibody testing required for these conditions, combined with the clinical expertise to interpret and act on the results, is not uniformly available across all medical centres in the region. Amrita Hospital’s Neuroimmunology Laboratory of Excellence offers a dedicated resource specifically for this purpose.
The Amrita Info Centre Sri Lanka team can help coordinate specialist consultations and investigations for patients seeking neurological evaluation in India. Further information about how the patient coordination process works is available on the Amrita Info Centre Sri Lanka website.
Frequently Asked Questions
How is an autoimmune neurological disorder diagnosed? Diagnosis is clinical – based on the combination of symptoms, neurological examination, brain imaging, cerebrospinal fluid analysis, and specialised antibody testing. No single test confirms a diagnosis alone. A negative antibody panel does not rule out autoimmune neurological disease; some patients with clinically suspected conditions are seronegative.
Can autoimmune neurological disorders be treated? Many can be substantially improved or stabilised with immunotherapy. First-line treatment typically involves corticosteroids, intravenous immunoglobulin, or plasmapheresis. The response and the degree of recovery depend on the specific condition and how early treatment begins.
Are these conditions related to a tumour? Some autoimmune neurological conditions are paraneoplastic – driven by an immune response to an underlying tumour. Investigation for an occult tumour is a standard part of the evaluation in selected cases. Not all autoimmune neurological conditions are tumour-related.
What if standard tests have come back normal? Routine investigations may appear normal in the early stages of autoimmune neurological disease. If clinical suspicion remains, specialised antibody testing and assessment by a neuroimmunologist may still identify an immune-mediated cause.
Can the Amrita Info Centre Sri Lanka help with a referral? Yes. The team can assist Sri Lankan patients in coordinating a neurological consultation at Amrita Hospital. You can contact the Amrita Info Centre Sri Lanka to discuss your specific situation.
Conclusion
Autoimmune neurological disorders are conditions that are treatable in many cases – but only if they are identified. The barrier to effective treatment is frequently not the availability of effective drugs; it is the delay between symptom onset and correct diagnosis.
The Neuroimmunology Laboratory of Excellence at Amrita Hospital, Kochi, was established specifically to address that diagnostic gap, providing comprehensive antibody testing and specialist clinical expertise within India’s first dedicated facility of this kind.
For Sri Lankan patients whose neurological presentation has not been fully explained, or who have received a diagnosis of epilepsy, encephalopathy, or a movement disorder that has not responded as expected to treatment, a specialist evaluation through this programme may provide clinically important answers.